Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes

Documenti analoghi

• The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL
  di: Markolf Hanefeld, et al.
  Pubblicazione: (2017-05-01)
• Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of Pioglitazone, Metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study
  di: Kleine Iris, et al.
  Pubblicazione: (2011-07-01)
• Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients
  di: He K, et al.
  Pubblicazione: (2014-06-01)
• The effect of combination therapy of sulfonylurea, metformin, and acarbose in type 2 diabetes mellitus patients
  di: Tri Murti Andayani,, et al.
  Pubblicazione: (2009-12-01)
• Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China.
  di: Shuyan Gu, et al.
  Pubblicazione: (2016-01-01)